RNK08179 / Ranok Therap - LARVOL DELTA

Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small molecule therapeutic agent (AACR 2024) - "Recent advancements in KRAS-targeted drugs, such as the FDA-approved KRAS(G12C) inhibitors sotorasib and adagrasib for NSCLC patients, have shown great promise in the clinic. RNK08179 effectively suppressed both KRAS signaling and RTK activation in MRTX1133-resistant cancer models, overcoming the compensatory resistance mechanisms observed with MRTX1133 alone. These findings highlight the potential of KRAS-CHAMPs as a novel, effective treatment strategy for KRAS-driven cancers, particularly those resistant to KRAS(G12D) inhibitors."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CDC37 • HSP90AA1 • KRAS